Clinician Knowledge and Practice Gaps for GLP-1 Drug Prescribing

What the researchers found

Survey reveals knowledge gaps and practice barriers among clinicians prescribing GLP-1 drugs, identifying education needs for optimal patient care.

Why it matters

These findings have practical implications for the growing number of patients using peptide-based therapies.

The numbers in context

Survey of community pharmacists in Saudi Arabia evaluating knowledge, attitudes, and practices regarding both GLP-1 RA and SGLT2 inhibitors.

How the study worked

Study methodology detailed in the full publication.

Who was studied

Community pharmacists in Saudi Arabia

What this study cannot tell us

Study limitations in the full publication.

How to read the evidence

Evidence level based on study design in publication.

When this study was published

Published in 2025.

The bigger picture

This study contributes to the expanding evidence for peptide therapeutics in clinical practice.

Questions still open

• What are the long-term implications?
• How do results compare to other evidence?
• What further research is needed?

Common questions

Read the original research

Knowledge, Counseling Practice, Perceived Barriers, and Clinical Decision-Making of Community Pharmacists in Saudi Arabia Regarding Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.

Diabetes, metabolic syndrome and obesity : targets and therapy, 18, 3093-3107

Citation

Alhomoud, Ibrahim S; Aldakhil, Sura A; Alhosan, Reema F; Alrashidi, Hanan S; Alsaqabi, Nada S; Aldugishem, Arjwan M; Alsuhibani, Abdulrahman A; Alrasheedy, Alian A. (2025). Knowledge, Counseling Practice, Perceived Barriers, and Clinical Decision-Making of Community Pharmacists in Saudi Arabia Regarding Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.. Diabetes, metabolic syndrome and obesity : targets and therapy, 18, 3093-3107. https://doi.org/10.2147/DMSO.S552287